Fairpointe Capital’s ResMed RMD Stock Holding History

Fairpointe Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$601K	Sell	3,098 -50,157	-94%	-$10.1M	0.91%	39
2020 Q4	$11.3M	Sell	53,255 -13,494	-20%	-$2.69M	2.08%	25
2020 Q3	$11.4M	Buy	66,749 +65,372	+4,747%	+$12.1M	1.83%	34
2020 Q2	$264K	Hold	1,377	–	–	0.04%	70
2020 Q1	$203K	Sell	1,377 -433	-24%	-$69K	0.03%	73
2019 Q4	$280K	Sell	1,810 -100	-5%	-$14.4K	0.02%	71
2019 Q3	$258K	Sell	1,910 -100	-5%	-$13.1K	0.01%	75
2019 Q2	$245K	Hold	2,010	–	–	0.01%	74
2019 Q1	$209K	Buy	+2,010	New	+$207K	0.01%	74

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fairpointe Capital's RMD Position: Q1 2021 in Review

Fairpointe Capital reduced its ResMed (RMD) stake by 94% in Q1 2021, selling an estimated $10.1M and leaving 3,098 shares worth $601K. The position accounts for 0.91% of the portfolio, ranked #39.

Fairpointe Capital first reported a position in RMD in Q1 2019 and has held it in 9 quarters since. The position peaked at $11.4M in Q3 2020. 663 funds tracked by Wall St. Rank hold RMD as of Q1 2021.

Fairpointe Capital held 3,098 shares of ResMed worth $601K as of Q1 2021.
Fairpointe Capital sold 50,157 ResMed shares in Q1 2021, an estimated $10.1M.
ResMed made up 0.91% of Fairpointe Capital's portfolio in Q1 2021, its #39 holding.
Fairpointe Capital first reported a position in ResMed in Q1 2019 and has held it in 9 quarters since.
Fairpointe Capital's ResMed position peaked at $11.4M in Q3 2020.
663 funds tracked by Wall St. Rank held ResMed as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.